These data, together with earlier reports [15,40], suggest that administration of sFasL could be effective in treating several angiogenesis-dependent diseases, such as cancer and chronic inflammatory diseases, explaining how sFasL protects against the development of experimental arthritis. The gene discussed is FASLG; the disease is arthritic joint disease.